Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Identifieur interne : 001286 ( Ncbi/Curation ); précédent : 001285; suivant : 001287Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
Auteurs : O R Obiako ; H M Murktar ; D. OgoinaSource :
- Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria [ 1115-2613 ]
Descripteurs français
- KwdFr :
- Afrique subsaharienne, Agents antiVIH (pharmacologie), Agents antiVIH (usage thérapeutique), Femelle, Génome, Humains, Infections à VIH (génétique), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Mutation, Mâle, Pays en voie de développement, Polymorphisme génétique, Résistance virale aux médicaments (génétique), Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique).
- MESH :
- génétique : Infections à VIH, Résistance virale aux médicaments, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- pharmacologie : Agents antiVIH.
- traitement médicamenteux : Infections à VIH.
- usage thérapeutique : Agents antiVIH.
- virologie : Infections à VIH.
- Afrique subsaharienne, Femelle, Génome, Humains, Mutation, Mâle, Pays en voie de développement, Polymorphisme génétique, Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Africa South of the Sahara, Anti-HIV Agents (pharmacology), Anti-HIV Agents (therapeutic use), Antiretroviral Therapy, Highly Active, Developing Countries, Drug Resistance, Viral (genetics), Female, Genome, HIV Infections (drug therapy), HIV Infections (genetics), HIV Infections (virology), HIV-1 (drug effects), HIV-1 (genetics), Humans, Male, Mutation, Polymorphism, Genetic.
- MESH :
- chemical , pharmacology : Anti-HIV Agents.
- chemical , therapeutic use : Anti-HIV Agents.
- geographic : Africa South of the Sahara.
- drug effects : HIV-1.
- drug therapy : HIV Infections.
- genetics : Drug Resistance, Viral, HIV Infections, HIV-1.
- virology : HIV Infections.
- Antiretroviral Therapy, Highly Active, Developing Countries, Female, Genome, Humans, Male, Mutation, Polymorphism, Genetic.
Abstract
The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance.
PubMed: 21526620
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000072
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000072
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000072
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001286
Links to Exploration step
pubmed:21526620Curation
No country items
O R Obiako<affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.</title><author><name sortKey="Obiako, O R" sort="Obiako, O R" uniqKey="Obiako O" first="O R" last="Obiako">O R Obiako</name><affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry></affiliation></author><author><name sortKey="Murktar, H M" sort="Murktar, H M" uniqKey="Murktar H" first="H M" last="Murktar">H M Murktar</name></author><author><name sortKey="Ogoina, D" sort="Ogoina, D" uniqKey="Ogoina D" first="D" last="Ogoina">D. Ogoina</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2010 Oct-Dec</MedlineDate></PubDate></date><idno type="RBID">pubmed:21526620</idno><idno type="pmid">21526620</idno><idno type="wicri:Area/PubMed/Corpus">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000072</idno><idno type="wicri:Area/PubMed/Curation">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000072</idno><idno type="wicri:Area/PubMed/Checkpoint">000072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000072</idno><idno type="wicri:Area/Ncbi/Merge">001286</idno><idno type="wicri:Area/Ncbi/Curation">001286</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.</title><author><name sortKey="Obiako, O R" sort="Obiako, O R" uniqKey="Obiako O" first="O R" last="Obiako">O R Obiako</name><affiliation><nlm:affiliation>Department of Medicine, Ahmadu Bello University Teaching Hospital Shika Zaria. reginaldobiako@yahoo.com</nlm:affiliation><wicri:noCountry code="subField">Ahmadu Bello University Teaching Hospital Shika Zaria</wicri:noCountry></affiliation></author><author><name sortKey="Murktar, H M" sort="Murktar, H M" uniqKey="Murktar H" first="H M" last="Murktar">H M Murktar</name></author><author><name sortKey="Ogoina, D" sort="Ogoina, D" uniqKey="Ogoina D" first="D" last="Ogoina">D. Ogoina</name></author></analytic><series><title level="j">Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria</title><idno type="ISSN">1115-2613</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa South of the Sahara</term><term>Anti-HIV Agents (pharmacology)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Antiretroviral Therapy, Highly Active</term><term>Developing Countries</term><term>Drug Resistance, Viral (genetics)</term><term>Female</term><term>Genome</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (genetics)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Male</term><term>Mutation</term><term>Polymorphism, Genetic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique subsaharienne</term><term>Agents antiVIH (pharmacologie)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Femelle</term><term>Génome</term><term>Humains</term><term>Infections à VIH (génétique)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Mutation</term><term>Mâle</term><term>Pays en voie de développement</term><term>Polymorphisme génétique</term><term>Résistance virale aux médicaments (génétique)</term><term>Thérapie antirétrovirale hautement active</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Africa South of the Sahara</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Drug Resistance, Viral</term><term>HIV Infections</term><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Infections à VIH</term><term>Résistance virale aux médicaments</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term><term>Developing Countries</term><term>Female</term><term>Genome</term><term>Humans</term><term>Male</term><term>Mutation</term><term>Polymorphism, Genetic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Afrique subsaharienne</term><term>Femelle</term><term>Génome</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Pays en voie de développement</term><term>Polymorphisme génétique</term><term>Thérapie antirétrovirale hautement active</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The introduction of the highly active antiretroviral therapy in the mid-1990s has significantly reduced morbidities and prolonged the lifespan of people living with HIV. However, the emergence of resistance to the antiretroviral drugs is becoming a major cause of treatment failure. While the problem of drug resistance is being tackled in developed countries, not much seem to be done in this regard in developing countries of Africa, Asia and Latin America. This review looked at the regional distribution of HIV groups and subtypes and how this has affected the pattern of antiretroviral resistance.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001286 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001286 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:21526620
|texte= Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21526620" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |